The Corporation focussed on the biology of healing has recently provided further top line data from its open label Phase 2 clinical trial in subjects suffering from idiopathic pulmonary fibrosis (IPF), following completion of the study. The results (now based on 40 patients) confirm earlier evidence of efficacy (30 patients) as both a mono-therapy, and in combination with the currently marketed treatments for IPF, nintendanib or pirfenidone. The evidence suggests the potential to outperform b
03 Mar 2017
PBI-4050 efficacy data on IPF bodes well for pivotal Phase 2/3 clinical trial due to initiate in Q2.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
PBI-4050 efficacy data on IPF bodes well for pivotal Phase 2/3 clinical trial due to initiate in Q2.
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
03 Mar 2017 -
Author:
Derren Nathan -
Pages:
6
The Corporation focussed on the biology of healing has recently provided further top line data from its open label Phase 2 clinical trial in subjects suffering from idiopathic pulmonary fibrosis (IPF), following completion of the study. The results (now based on 40 patients) confirm earlier evidence of efficacy (30 patients) as both a mono-therapy, and in combination with the currently marketed treatments for IPF, nintendanib or pirfenidone. The evidence suggests the potential to outperform b